Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline Deferred Investment Award programme.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific compensation-related transactions involving two executives.
| Executive | Position | Instrument | Transaction Date | Volume | Price | Estimated Gross Value |
|---|---|---|---|---|---|---|
| Mr. J Ford | SVP & General Counsel | American Depositary Shares (ADSs) | 2021-02-17 | 6,320 | $35.65 | $225,308 |
| Ms. D Waterhouse | CEO of ViiV Healthcare | Ordinary Shares | 2021-02-17 | 15,302.697 | £12.73 | £194,803.33 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. The transactions represent the vesting of awards granted in September 2018 (Mr. Ford) and February 2015 (Ms. Waterhouse), resulting in cash payments in lieu of share delivery.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity-based compensation events.
Investor Verification Points
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award programme.
- Confirm the tax withholding implications for the cash payments received by Mr. Ford and Ms. Waterhouse.
- Check the market price of GSK ADSs and Ordinary Shares on February 17, 2021, to validate the transaction pricing.
- Review the company's annual report (Form 20-F) for broader context on executive compensation and equity plans.